About 298 results

ALLMedicine™ Protoporphyria Center

Research & Reviews  101 results

Hematopoietic stem cell transplant for erythropoietic porphyrias in pediatric patients.
Pediatric Blood & Cancer; Wang YM, Gloude NJ et. al.

Jul 11th, 2021 - Cutaneous, hematopoietic, and hepatic manifestations of congenital erythropoietic porphyria (CEP) and erythropoietic protoporphyria (EPP) can be debilitating. We present our institution's experience with five patients with porphyria who underwent ...

Erythropoietic Protoporphyria.
Journal of Cutaneous Medicine and Surgery; Liu ZH, Shen H

May 5th, 2021 - Erythropoietic Protoporphyria.|2021|Liu ZH,Shen H,|

A mutation in the iron-responsive element of ALAS2 is a modifier of disease severity in...
Haematologica Ducamp S, Luscieti S et. al.

Feb 19th, 2021 - A mutation in the iron-responsive element of ALAS2 is a modifier of disease severity in a patient suffering from CLPX associated erythropoietic protoporphyria.|2021|Ducamp S,Luscieti S,Ferrer-Cortès X,Nicolas G,Manceau H,|genetics,metabolism,diagn...

Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.
Expert Review of Clinical Pharmacology; Wensink D, Wagenmakers MAEM et. al.

Jan 29th, 2021 - Introduction: In erythropoietic protoporphyria (EPP), an inherited disorder of heme biosynthesis, accumulation of protoporphyrin IX results in acute phototoxicity. EPP patients experience severe burning pain after light exposure, which results in ...

see more →

Drugs  2 results see all →

News  16 results

Novel Oral Drug Improves Sunlight Tolerance in Patients With Erythropoietic Protoporphyria

Aug 25th, 2020 - Dersimelagon, a novel once-daily oral selective melanocortin-1 receptor agonist, significantly boosted sunlight tolerance in patients with erythropoietic protoporphyria in a multicenter, phase 2, randomized trial, Kirstine Belongie, PhD, reported ...

FDA Approvals, Highlights, and Summaries: Dermatology

Feb 27th, 2020 - Aklief (trifarotene) Trifarotene is an agonist of retinoic acid receptors (RARs), with particular activity at the gamma subtype of RAR. Stimulation of RARs results in modulation of target genes that are associated with various processes, including...

FDA approves afamelanotide for treatment of rare condition with light-induced pain
Christopher Palmer

Oct 8th, 2019 - The Food and Drug Administration has approved afamelanotide (Scenesse) to “increase pain-free light exposure” in adults with a history of phototoxic reactions from erythropoietic protoporphyria, a rare condition that causes extremely painful react.

FDA OKs New Treatment Afamelanotide for Phototoxic Reactions

Oct 8th, 2019 - The US Food and Drug Administration (FDA) has approved afamelanotide (Scenesse, Clinuvel), the first treatment to ease phototoxic reactions in patients with erythropoietic protoporphyria, according to an agency news release. Erythropoietic protopo...

Team identifies mutation that causes EPP
HT Staff

Sep 10th, 2017 - Red blood cells Researchers say they have discovered a genetic mutation that triggers erythropoietic protoporphyria (EPP). The team performed genetic sequencing on members of a family from Northern France who had EPP of a previously unknown geneti.

see more →